Financing round · Healthtech
HighLife raises €80m to advance transcatheter mitral-valve replacement
Its catheter-delivered system is moving toward a US pivotal study as the company builds its European commercial presence.
A valve replacement delivered through a catheter
HighLife’s system is designed to replace the mitral valve through a catheter inserted via the femoral vein. Its valve-in-ring approach uses a patient’s existing surgical repair ring as an anchor, offering structural-heart teams a route to treat severe mitral regurgitation without open-heart surgery.
The company says the financing will support a US pivotal study and European commercialization. The two tracks mark the transition from clinical development toward broader use, while US pivotal testing remains ahead.
Use of funds
Accelerate commercial expansion across Europe
Advance the US pivotal clinical development program
Funding history
Financing round · This round€80M